HIV Protease

HIV Protease Full Name

human immunodeficiency virus protease

HIV Protease Introduction

HIV-1 protease (Human immunodeficiency virus 1) is a homodimeric aspartyl enzyme essential for viral maturation. It processes the Gag and Gag-Pol polyproteins into functional structural and enzymatic components, enabling the production of infectious virions. Each protease monomer contributes residues to the active site, forming a catalytic pocket that recognizes and cleaves specific peptide bonds within the polyprotein. Structural analyses reveal that the active site and flap regions are critical determinants of substrate binding and enzymatic activity. Drug-resistant mutations frequently arise in these regions, altering pocket geometry and dynamic behavior while preserving catalytic function, thereby enabling viral survival under therapeutic pressure. Despite this variability, the core architecture of the protease remains conserved, providing a stable target for inhibitor design. The success of protease inhibitors in antiretroviral therapy validates the enzyme's central role in the viral life cycle and highlights the therapeutic importance of structure-based drug development.

Protease inhibitors (PIs) function primarily as competitive inhibitors that mimic the transition state of peptide cleavage, occupying the active site and preventing substrate processing. Early generations of inhibitors employed hydroxyethylene or hydroxyethylamine scaffolds to replicate key interactions within the catalytic pocket. Subsequent advances produced compounds such as darunavir, which utilizes bis-tetrahydrofuran (bis-THF) moieties and extensive hydrogen-bond networks to engage both active-site residues and protease backbone atoms. This binding strategy enhances inhibitor robustness against resistance mutations because backbone interactions are less susceptible to sequence variation than side-chain contacts. Nonpeptide inhibitors, including cyclic ureas, demonstrate that alternative chemistries can achieve potent protease inhibition and broaden therapeutic options. Resistance remains a persistent challenge: mutations in substrate-binding subsites and flap regions reduce inhibitor affinity while maintaining substrate processing. To address this, substrate-envelope-guided design strategies aim to shape inhibitors that conform to the three-dimensional envelope occupied by natural substrates, minimizing the impact of resistance-associated structural changes. Complementary approaches, such as targeting protease dimerization to prevent active enzyme assembly, further diversify therapeutic strategies and may suppress viral replication even in resistant strains.

Clinical and translational considerations extend beyond antiviral efficacy to encompass drug resistance and host-related effects. Protease mutations that confer resistance underscore the need for ongoing surveillance and individualized therapy guided by genotypic analysis. Cross-reactivity between HIV-1 and HIV-2 proteases complicates treatment in regions where both viruses circulate; although several inhibitors retain activity against HIV-2, differential sensitivity necessitates specific evaluation of drug efficacy for each variant. Off-target effects of protease inhibitors on host cellular pathways also influence clinical outcomes. Some inhibitors modulate apoptotic signaling in immune cells, with context-dependent effects on T-cell survival that may impact immune reconstitution. Additionally, metabolic and vascular side effects—such as endothelial dysfunction and alterations in bilirubin metabolism—highlight the importance of balancing antiviral potency with safety and tolerability. Future therapeutic development therefore prioritizes inhibitors with broad activity against resistant proteases, reduced off-target toxicity, and improved pharmacokinetic profiles. Continued integration of structural biology, resistance surveillance, and clinical pharmacology remains essential for advancing protease-targeted therapies and sustaining long-term viral suppression.

Alternate Names for HIV Protease

HIV-1 protease; Human immunodeficiency virus protease; PR; Retropepsin; HIV protease

• 1. Koh Y., et al. Potent Inhibition of HIV-1 Replication by Novel Non-peptidyl Small Molecule Inhibitors of Protease Dimerization. Journal of Biological Chemistry. 2007;282(39):28709–28720.
  2. Kovalevsky A., et al. Structural Evidence for Effectiveness of Darunavir and Two Related Antiviral Inhibitors against HIV-2 Protease. Journal of Molecular Biology. 2008;384(1):178–192.
  3. Mahdi M., et al. A Modular System to Evaluate the Efficacy of Protease Inhibitors against HIV-2. PLOS ONE. 2014;9(11):e113221.